Cidara Therapeutics, Inc.
CDTX
$20.69
$1.256.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -227.23% | -- | -- | -221.38% | 64.72% |
| Total Depreciation and Amortization | -3.28% | -- | -- | 43.59% | 77.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -33.33% | 84.62% |
| Total Other Non-Cash Items | 86.79% | -- | -- | -9.02% | 4.37% |
| Change in Net Operating Assets | 195.63% | -- | -- | 124.47% | -267.08% |
| Cash from Operations | 19.84% | -- | -- | 47.78% | -678.58% |
| Capital Expenditure | 100.00% | -- | -- | 87.08% | -41.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | 87.08% | -41.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.33% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54,058.79% | -- | -- | -1,262.50% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 286.01% | -- | -- | 47.56% | -632.50% |